Association of Hematological Parameters with Insulin Resistance and β-Cell Dysfunction in Nondiabetic Subjects

被引:82
作者
Hanley, Anthony J. G. [1 ,2 ,5 ]
Retnakaran, Ravi [2 ,5 ]
Qi, Ying [5 ]
Gerstein, Hertzel C. [7 ,8 ]
Perkins, Bruce [2 ]
Raboud, Janet [3 ,4 ,6 ]
Harris, Stewart B. [9 ]
Zinman, Bernard [2 ,5 ,6 ]
机构
[1] Univ Toronto, Univ Hlth Network, Dept Nutr Sci, Toronto, ON M5S 3G3, Canada
[2] Univ Toronto, Univ Hlth Network, Div Endocrinol, Toronto, ON M5S 3G3, Canada
[3] Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON M5S 3G3, Canada
[4] Univ Toronto, Univ Hlth Network, Div Infect Dis, Toronto, ON M5S 3G3, Canada
[5] Mt Sinai Hosp, Leadership Sinai Ctr Diabet, Toronto, ON M5G 2C4, Canada
[6] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 2C4, Canada
[7] McMaster Univ & Hamilton Hlth Sci, Div Endocrinol & Metab, Hamilton, ON L8Z 3N5, Canada
[8] McMaster Univ & Hamilton Hlth Sci, Dept Med, Populat Hlth Res Inst, Hamilton, ON L8Z 3N5, Canada
[9] Univ Western Ontario, Ctr Studies Family Med, London, ON N6A 5B8, Canada
基金
加拿大健康研究院;
关键词
ORAL GLUCOSE-TOLERANCE; TYPE-2; DIABETES-MELLITUS; BLOOD-VISCOSITY; CARDIOVASCULAR-DISEASE; RISK-FACTORS; HEMATOCRIT; SENSITIVITY; MEN; SECRETION; INFLAMMATION;
D O I
10.1210/jc.2009-0719
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Previous studies reported independent associations of hematological parameters with risk of incident type 2 diabetes, although limited data are available on associations of these parameters with insulin resistance (IR) and (especially) pancreatic beta-cell dysfunction in large epidemiological studies. Our objective was to evaluate the associations of hematological parameters, including hematocrit (HCT), hemoglobin (Hgb), red blood cell count (RBC), and white blood cell count with IR and beta-cell dysfunction in a cohort of nondiabetic subjects at high metabolic risk. Methods: Nondiabetic subjects (n = 712) were recruited in Toronto and London, Ontario, Canada, between 2004 and 2006, based on the presence of one or more risk factors for type 2 diabetes mellitus including obesity, hypertension, a family history of diabetes, and/or a history of gestational diabetes. Fasting blood samples were collected and oral glucose tolerance tests administered, with additional samples for glucose and insulin drawn at 30 and 120 min. Measures of IR included the homeostasis model assessment (HOMA-IR) and Matsuda's insulin sensitivity index, whereas measures of beta-cell dysfunction included the insulinogenic index divided by HOMA-IR as well as the insulin secretion-sensitivity index-2. Associations of hematological parameters with IR and beta-cell dysfunction were assessed using multiple linear regression and analysis of covariance with adjustments for age, gender, ethnicity, smoking, cardiovascular disease, systolic and diastolic blood pressure, and waist circumference. Results: HOMA-IR increased across quartiles of HCT, Hgb, RBC, and white blood cell count after adjustment for age, gender, ethnicity, and smoking (all P (trend) <0.0001). Similarly, there was a strong stepwise decrease in the Matsuda's insulin sensitivity index across increasing quartiles of these hematological measures (all P (trend) <0.0001). The associations remained significant after further adjustment for previous cardiovascular disease, blood pressure, and waist circumference (all P (trend) <0.0001). Similarly, there was a strong pattern of decreasing beta-cell function across increasing quartiles of all hematological patterns (all P (trend) <0.0001). The findings for HCT, Hgb, and RBC were attenuated slightly after full multivariate adjustment, although the trend across quartiles remained highly significant. Conclusion: These findings suggest that standard, clinically relevant hematological variables may be related to the underlying pathophysiological changes associated with type 2 diabetes mellitus. (J Clin Endocrinol Metab 94: 3824-3832, 2009)
引用
收藏
页码:3824 / 3832
页数:9
相关论文
共 38 条
[31]   ISCHEMIC-HEART-DISEASE - ASSOCIATION WITH HEMATOCRIT IN THE BRITISH-REGIONAL-HEART-STUDY [J].
WANNAMETHEE, G ;
SHAPER, AG ;
WHINCUP, PH .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1994, 48 (02) :112-118
[32]  
WANNAMETHEE G, 1994, THROMB HAEMOSTASIS, V72, P58
[33]   HEMATOCRIT, HYPERTENSION AND RISK OF STROKE [J].
WANNAMETHEE, G ;
PERRY, IJ ;
SHAPER, AG .
JOURNAL OF INTERNAL MEDICINE, 1994, 235 (02) :163-168
[34]   Hematocrit and risk of NIDDM [J].
Wannamethee, SG ;
Perry, IJ ;
Shaper, AG .
DIABETES, 1996, 45 (05) :576-579
[35]  
Wareham N J, 1995, Diabet Med, V12, P931
[36]   OBESITY, VERY LOW-DENSITY LIPOPROTEINS, AND GLUCOSE-INTOLERANCE OVER 14 YEARS - THE FRAMINGHAM-STUDY [J].
WILSON, PW ;
MCGEE, DL ;
KANNEL, WB .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1981, 114 (05) :697-704
[37]   Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β [J].
Zeender, E ;
Maedler, K ;
Bosco, D ;
Berney, T ;
Donath, MY ;
Halban, PA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (10) :5059-5066
[38]   Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial [J].
Zinman, B. ;
Harris, S. B. ;
Gerstein, H. C. ;
Young, T. K. ;
Raboud, J. M. ;
Neuman, J. ;
Hanley, A. J. G. .
DIABETES OBESITY & METABOLISM, 2006, 8 (05) :531-537